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Abstract 
Objective: The aim of this study is to review literature about how the pharmacist’s role as vaccination providers has been financially 
and clinically measured. 
Methods: A broad literature search was conducted up to May 2016 to identify economic or clinical data on pharmacy vaccinations. 
MEDLINE® and PUBMED databases were searched for publications useful or potentially useful for this review. The NIH and CDC websites 
were also searched for relevant materials. Search terms included vaccination, pharmacist, economic, pharmacoeconomics, cost, 
benefits cost-effectiveness, physicians, immunizations, vaccinations, pharmacy vaccines, cost, physician vaccines, financial, benefit, 
ambulatory pharmacist vaccination, clinical pharmacist, economics, pharmacist vaccine impact. 
Results: The search yielded a total of 68 articles of which 12 met the criteria to be included in this review. After examining articles for 
relevance to pharmacy vaccinations, two tables were created to highlight the clinical and economic advantages of the pharmacist as 
a vaccinator. 
Conclusion: Pharmacists who administer vaccines are an underutilized provider. This literature review reveals a pattern among studies 
measuring the pharmacist’s impact on vaccination rates, patient preferences, and cost savings. Pharmacists have a history of 
demonstrated dependability, accuracy, and cost effectiveness. State laws, collaborative agreements, and health plans have continued 
to prevent patients from using the pharmacy to receive the CDC recommended vaccines. These barriers ultimately delay the Healthy 
People 2020 goals. 
 
 
Introduction/Background  
Increasing vaccination rates to reduce infectious diseases 
remains one of the Healthy People 2020 objectives set forth by 
the United States Office of Disease Prevention and Health 
Promotion.1, 2 Vaccine innovation and increased vaccination 
rates were linked with increased survival in the 20th century.  
However, certain infectious diseases that can be prevented by 
vaccines, still remain a major cause of morbidity and mortality.2 
Currently there are 17 vaccine-preventable diseases in the 
United States1, including influenza.  Although preventable, 
influenza is one of the leading infections in the United States 
and accounts for substantial spending on the consequences 
associated with the virus.2  
 
Vaccines remain the most cost-effective intervention in clinical 
prevention of infectious disease and their proper use is 
essential.2 Specifically, children’s vaccination programs yield a 
higher return on investment.  Children receiving their 
vaccinations according to the CDC schedule saves 33,000 lives, 
prevents 14 million instances of disease, reduces health care 
cost by $9.9 billion, and saves $33.4 billion in indirect cost. In 
spite of the available vaccines, about 42,000 of adults and 300 
children die each year from vaccine preventable diseases.2 
 
The pharmacists’ role as vaccinators dates back to the 1800’s. 
The first organized formal vaccination training for pharmacists  
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took place in Seattle, Washington in 1994. In November 1996, 
the American Pharmacists Association began its nationally 
recognized training program for pharmacists; Pharmacy-Based 
Immunization Delivery: A National Certificate Program for 
Pharmacists. Today, pharmacists have authority to administer 
vaccines in all 50 states, including the District of Columbia and 
Puerto Rico.3  
 
Pharmacists are immunization advocates and act as educators, 
facilitators, and vaccinators.4 Pharmacists provide education 
that helps dispel the many myths concerning vaccinations that 
dissuade the public from receiving them.  Among the myths are 
vaccinations’ link to autism, vaccinations cause sudden infant 
death syndrome, vaccines contain harmful ingredients that can 
affect children, vaccines cause neurological conditions (i.e., 
seizures), children are given excessive vaccines in a short period 
of time, and vaccines are derived from aborted fetuses.4 
 
Pharmacists are trained to deliver adult vaccines, child vaccines 
and travel vaccines, but vaccination services are often subject 
to state legislation and physician protocols. State restrictions 
limit pharmacists from vaccinating patients in need by dictating 
the types of vaccines administered, the age of patients, type of 
order requiring a  prescription, and standing order protocols.4 
However, these restrictions have been suspended in times of 
pandemics, such as the H1N1 influenza, when additional 
vaccinators were needed.5 Additionally, the community 
pharmacy is equipped to deliver vaccines. The pharmacy has 
proper refrigeration, documentation, and emergency supplies. 
The pharmacy often has a private area for vaccine 
administration, which is useful for patient monitoring in case of 
allergic reactions. 
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A pharmacist offers significant clinical and financial benefits 
through vaccination services.  Administering vaccines in a 
community pharmacy has become accepted by the public, 
especially for influenza vaccine.  Commercial and governmental 
health plans are beginning to provide coverage for those 
patients receiving vaccinations at pharmacy locations.  
However, health plans stipulate vaccine coverage and may not 
always pay for all recommended vaccines.6 The aim of this study 
is to review literature where the pharmacist as a vaccinator, has 
been financially and clinically assessed.  
 
Objectives 
The objectives for this review were to examine studies where 
the pharmacists served as a vaccinator and to document the 
clinical and financial impacts.  
 
Methods 
A broad literature search was conducted to identify economic 
and clinical data on pharmacists vaccinating in pharmacies. 
MEDLINE®, PUBMED, NIH, and CDC databases were searched 
for publications useful or potentially useful in this collection of 
data. Search terms included vaccination, pharmacist, economic, 
pharmacoeconomics, cost, benefits cost-effectiveness, 
physicians, immunizations, vaccinations, pharmacy vaccines, 
cost, physician vaccines, financial, benefit, ambulatory 
pharmacist vaccination, clinical pharmacist, economics, 
pharmacist vaccine impact. Articles found were examined for 
relevance and a data table was created outlining areas where 
additional research is needed. 
 
Results 
The data examined in the literature review can be found in 
Tables 1 and 2. The following are modified key points from the 
original article.  
 
Vaccinations Administered During Off-Clinic Hours at a 
National Community Pharmacy: Implications for Increasing 
Patient Access and Convenience:7  
 Researchers retrospectively reviewed data for all 
vaccinations administered at Walgreens pharmacies 
between August 2011 and July 2012.  Specifically 
comparing between two time periods (standard clinic 
hours [9:00 am – 6:00 pm] and off-clinic hours), they 
analyzed the type of vaccine given as well as patient 
populations in order to assess implications for access 
and convenience.  
 The following groups were most likely to be vaccinated 
during off-clinic hours: younger patients, patients 
living in metropolitan/micropolitan areas, patients 
living in states that allow pharmacists to administer all 
CDC-recommended vaccines, those receiving travel 
vaccines, and patients who receive > 2 vaccines in one 
year; this study found no difference in off-clinic hour 
use in patients who used the pharmacy for only 
vaccination vs those who were also picking up 
prescription.  
 Vaccines with the greatest proportion administered 
during off-clinic hours were typhoid (41.5%), Tdap 
(34.5%), HPV (33.8%), varicella zoster (31.6%), 
influenza (31.5%), hepatitis (31.4%), and yellow fever 
(30.8%).   
 More than 1 million vaccinations took place during 
lunch hours (11:00 am to 1:00 pm) out of total 
vaccinated administered of 6,250,402.  
 The proportion vaccinated during off- clinic hours was 
similar for patients with or without chronic conditions.  
 More than 150,000 vaccinations occurred during the 
overnight hours of 10:00 pm to  
9:00 am.  
 
Community Pharmacist-Administered Influenza Immunization 
Improves Patient Access to Vaccines: 8 
 Research pharmacists collected survey data from 4 
different community pharmacy locations in Toronto 
from October 2013 to November 2013 in order to 
describe demographics and possible patient risk 
factors for receiving the influenza vaccine in a 
community setting.  The study also assesses patient 
experiences and perceptions.  
 Convenience of the pharmacist is a major factor to 
patient satisfaction. 
 99% of surveys (1502 surveys total) indicated patients 
would recommend family and friends to be vaccinated 
by a pharmacist.    
 One-third indicated that they would not have been 
vaccinated this year if pharmacist-administered 
vaccination were not available. 
 No patient was dissatisfied with the vaccination 
provided by the pharmacist, pharmacy service, and 
injection technique. Rather, all patients surveyed were 
satisfied or very satisfied with pharmacy service and 
injection technique. 
 All patients were either very comfortable or 
comfortable with their vaccine being administered by 
the pharmacist.  
 
The Effect of Pharmacist Intervention on Herpes Zoster 
Vaccination in Community Pharmacies: 9 
 In this prospective intervention study, patients 
presenting to independent pharmacies across 
Tennessee were asked to complete a survey after 
receiving their vaccination. The survey aimed to 
capture patients’ comfort level, sources of vaccination 
education and sources of influence.  Questions such 
as, “How did you hear about the Shingles vaccine?” 
required patients to select from the following options: 
doctor, family/friend, pharmacist, flyer from your 
pharmacy, newspaper, letter in the mail from 
pharmacy and other.  
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 The most effective method of pharmacy-driven 
intervention was the personalized letter. 
 Patients were more likely to receive a vaccine from 
reading pharmacy-driven interventions than by 
influences from a physician (P<0.0001), family/friend 
source (P<0.0001), or other source (P<0.0001).  
 Of the 205 patients, 204 indicated they were very 
comfortable or somewhat comfortable with vaccines 
delivered by the pharmacist. 
 When asked, “Why did you decide to get vaccinated 
against shingles?” There was no statistical difference 
between pharmacy-based sources and family/friends 
(P=0.1025). 
 
“It’s Easier in Pharmacy”: Why Some Patients Prefer to Pay for 
Flu Jabs Rather Than Use the National Health Service: 10 
 Retrospective data was collected in England during the 
2012-2013 flu season to assess why patients eligible 
for free vaccination through the National Health 
Service (NHS) opted to pay privately.  A total of 479 
pharmacies provided data.  Thirteen private service 
pharmacies were selected to further identify reasons 
for choosing to pay privately.  They consisted of the 
top 100 performing pharmacies and 921 patients who 
had a vaccination were approached with a 
questionnaire. 
 Of the 921 patients, 199 (22%) were eligible for free 
vaccination and 100 chose not to use the free, NHS 
option.  Primary reason was due to the inconvenience 
of going to a general practitioner. 
 Other reasons for visiting a pharmacy for a flu 
vaccination included: location/hours convenience, 
pharmacy/staff environment preference, in-store 
advertisement, and vaccine availability. 
 Reasons given for not visiting a general practitioner  
to get a flu vaccination: inconvenience of getting to  
the physician office (i.e., GP surgery), difficulty in 
scheduling an appointment, and unavailability of 
vaccines. 
 
Who Uses Pharmacy for Flu Vaccinations? Population Profiling 
Through a UK Pharmacy Chain: 11 
 Pharmacists asked patients who received a vaccination 
between October 2014 and March 2015 to complete a 
questionnaire. Data was electronically recorded for 
150, 997 vaccinations across 1,201 pharmacies in 
England. Typically, the pharmacy is accessible by 
frontline healthcare workers and people of working 
age from various demographic areas. 
 Every patient cited convenience or accessibility as the 
primary reason for why they chose to receive their flu 
vaccination from a pharmacy, regardless of whether it 
was NHS or privately funded. 
 
 
 The majority (85.6 %) of all flu vaccinations were 
recorded between 9 am and 5 pm with peaks occurring 
between 11 am and 1 pm (24.0 %). 
 
Individual-and Neighborhood-Level Characteristics Associated 
With Support Of In-Pharmacy Vaccination Among ESAP-
Registered Pharmacies: Pharmacists’ Role in Reducing Racial/ 
Ethnic Disparities in Influenza Vaccinations in New York City:12 
 Using the Pharmacies as Resources Making Links to 
Community Services (PHARM-Link) community-based, 
randomized pharmacy-intervention study in New 
York, 477 pharmacy staff registered with the Expanded 
Syringe Access Program (ESAP) in Harlem, Lower 
Manhattan, the Bronx, Brooklyn and Queens were 
asked to complete a survey in order to assess support 
of in-pharmacy vaccinations.  Survey question was 
“How much do you support vaccination services being 
provided in your pharmacy?” 
 Pharmacies in neighborhoods with a high percent of 
minority residents were significantly less likely (PR, 
0.94; 95%CI, 0.88–1.00, p=0.0468) to support in-
pharmacy vaccination compared with those with 
fewer minorities. 
 Pharmacies in neighborhoods with more foreign-born 
residents were marginally more likely to support in-
pharmacy vaccination (PR, 1.06; 95%CI 0.99–1.13, 
p=0.0854). 
 This study found that pharmacy staff support of in-
pharmacy vaccination services was high overall (86% 
of 437 surveyed).  
 Initiatives are needed to increase knowledge about 
the importance of lower vaccination rates as well as 
increased influenza-related mortality among 
pharmacy staff and residents working in minority 
neighborhoods to help boost interest of in-pharmacy 
vaccinations in these specific communities.  
 
The Role of Pharmacists in the Delivery of Influenza 
Vaccinations: 13 
 This study was a secondary analysis of the Behavioral 
Risk Factor Surveillance System (BRFSS) that was 
conducted in 1995 and 1999.   
 In states where pharmacists are allowed to provide 
vaccinations, both individuals aged 18–64 years (odds 
ratio (OR) = 1.27; 95% confidence interval (CI) = 1.19–
1.36) and individuals aged 65 years and older (OR = 
1.22; 95% CI = 1.07–1.39) were more likely to receive 
influenza vaccines than individuals in states where 
pharmacists cannot provide vaccinations. 
 Individuals who were Black or had a self-perceived 
cost barrier to receiving health care had a decreased 
likelihood of receiving vaccinations in both age 
categories.  
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Pharmacists as Providers: Targeting Pneumococcal 
Vaccinations to High-Risk Populations:14 
 Between August 1, 2010 and November 14, 2010, a 
total of 2,095,748 patients received influenza 
vaccinations at Walgreens.  At the same time of the flu 
vaccine, the pharmacist also recommended the 
PPSV23 if any risk was identified.  Of the total study 
population, 1,343,751 (64%) persons were considered 
at-risk and met the ACIP recommendation for PPSV23.  
 921,624 patients (69%) were at-risk because they were 
age 65 and older; 22,127 patients (31%) were at risk 
because they had one of the ACIP comorbid conditions 
and were aged 2–64.  
 Pharmacists were especially effective at reaching 
patients aged 60–70 years, who are likely to be at-risk 
not only due to age but also due to comorbid 
conditions. Patients aged 60–70 years had the highest 
PPSV23 vaccination rate (6.60%, 26,430/400,454) of 
any age group.  
 
Improved Influenza Vaccination Rates in a Rural Population as 
a Result of a Pharmacist-Managed Immunization Campaign: 15  
 In 1999, a pharmacy team conducted a manual chart 
review of 2,271 charts in a rural primary care clinic and 
collected patient demographic data including 
influenza vaccine history and influenza 
contraindications. They identified 657 patients who 
had indications for the vaccine. The team also 
developed education packets, which were distributed 
to the patients identified in the chart review. 
Vaccinations were given in specially designated clinics 
and during routine clinic visits. Campaign success and 
reasons why patients remained unvaccinated were 
determined by follow-up surveys.  
 A total of 283 patients completed a survey designed to 
capture factors that convinced and reminded patients 
to get their vaccination. Of these, 199 respondents 
were patients with positive indications who were 
vaccinated against influenza and had received the 
education packet.  
 This study demonstrated that this pharmacy-directed 
program significantly increased vaccinations by 95% 
for a group of high-risk patients in a rural community 
practice.  
 Patients consistently identified the mailed education 
packet and their health care provider as the top factors 
that had convinced and reminded them to get 
vaccinated.  
 The most common suggestions for improving the 
vaccination program included providing more days 
and times available for vaccine administration and 
increasing the staff to administer vaccinations. 
 
 
 
Impact of Pharmacist Integration in a Pediatric Primary Care 
Clinic on Vaccination Errors: A Retrospective Review:16 
 At the Nationwide Children’s Hospital in Columbus, 
Ohio, vaccine error rates and missed opportunities 
were compared between two pediatric primary care 
clinics during April, May, and June 2011.  Staffing levels 
were consistent throughout both clinics and included 
attending physicians and resident physicians, 
however, different individuals would staff each clinic.  
Specifically, the “intervention clinic” had a full-time, 
board-certified ambulatory clinical pharmacist who 
provided vaccination education to provider and 
patients.  The “comparison clinic” did not include 
pharmacy personnel to ensure appropriate use of 
vaccines.  
 After researchers reviewed 900 total randomized 
encounters from both clinics, 19 errors were found in 
the evaluation. With 2 errors identified in the 
comparison clinic and 17 from the “intervention 
clinic,” the error rate was 0.28% and 2.7%, respectively 
(P = 0.0021).  
 Further research of pharmacist involvement in several 
areas of vaccine use is needed. This study did not 
include an economic evaluation of improved use of 
vaccines. Additional research investigating the 
economic implications of pharmacist integration into 
the primary care setting on vaccine use is also needed.  
 Missed opportunities were defined as vaccine doses 
due at date of encounter and not given. In the 
comparison clinic, 132 randomized encounters were 
found to have greater than or equal to one missed 
opportunity, compared with 46 randomized 
encounters in the intervention clinic (P<0.0001).  
 Hepatitis A vaccine and Hepatitis B vaccine were the 
most common vaccines associated with missed 
opportunities.  
 
Costs of Adult Vaccination in Medical Settings and Pharmacies: 
An Observational Study:17 
 The objective of this observational retrospective study 
was to compare the direct costs paid in different 
settings (i.e., physician offices, other medical settings, 
and pharmacies) for adult vaccinations of zoster, 
pneumococcal, and influenza.  
 The costs paid for vaccination-included costs 
associated with the vaccine product, administration, 
dispensing, and outpatient visit fees. Visit fees for 
medical settings were included only in those instances 
where vaccination was determined to be the trigger 
for the visit, i.e., the only service provided during the 
visit (≤2% of instances). 
 Patients’ mean (SD) ages across settings were 65.8 
(6.7) years for zoster vaccine, 58.2 (12.2) years for 
pneumococcal vaccine, and 51.4 (13.8) years for 
influenza vaccine. 
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 The mean (SD) total costs, which included health plan 
and enrollee payment, per vaccine administration at 
physician offices, other medical settings, and 
pharmacies were as follows: 
o Physician offices: zoster vaccine—$208.72 
(42.10), pneumococcal vaccine—$65.69 (27.54), 
and influenza vaccine—$29.29 (15.29)  
(P < 0.05). 
o Other medical settings (i.e., inpatient and 
outpatient hospital, emergency department): 
zoster vaccine—$209.51 (50.83), pneumococcal 
vaccine—$72.11 (49.95), and influenza 
vaccine—$24.20 (13.12) (P < 0.05). 
o Pharmacies: zoster vaccine—$168.50 (15.66), 
pneumococcal vaccine—$54.98 (9.72) (P < 0.05), 
influenza vaccine—21.57 (6.63) (P < 0.05). 
 The data may help payers and policymakers 
understand the economic value of adult vaccination in 
different settings, especially in pharmacies. 
 For all 3 vaccines, the costs paid were significantly 
lower in pharmacies than in either physician offices or 
other medical settings (P < 0.05).  
 For zoster vaccination, patients paid the least out-of-
pocket at physician offices ($16.95 [43.85], P < 0.05), 
whereas insurers paid the least at pharmacies 
($145.72 [$38.54], P < 0.05). 
 For both the pneumococcal and influenza vaccines, 
patients paid the least at pharmacies, while insurers 
paid the least in other medical settings, and the most 
at physician offices. 
 For zoster vaccination, patients paid the least out-of-
pocket at physician offices, whereas insurers paid the 
least at pharmacies. 
 From the patient perspective, costs paid were lower in 
pharmacies than in other medical settings for all 3 
vaccinations and lower than in physician offices for 
pneumococcal and influenza vaccines. 
 Researchers conducted telephone interviews with 
representatives from each setting in 2004 to 
understand the costs of vaccination delivery in 
nontraditional settings. They found that vaccination 
delivery cost less in the nontraditional settings ($17 in 
mass vaccination settings, $12 in pharmacies) 
compared with physician offices ($29).  Additionally, 
they found that vaccination in nontraditional settings 
was projected to be cost saving for healthy adults aged 
≥50 years and for high-risk adults of all ages. 
 Pharmacies had lower average direct costs paid per 
adult vaccination than physician offices and other 
medical settings—by 16%-26% and 11%-20%, 
respectively—when both health plan and enrollees’ 
perspectives were considered. 
 
 
Non-Traditional Settings for Influenza Vaccination of Adults: 
Costs And Cost Effectiveness:18 
 Using detailed phone interviews, researchers 
evaluated the costs of influenza vaccination in non-
traditional settings.  Target age population included 
18-49, 50-64, and ≥65 years with either high risk or low 
risk for influenza-related complications. Probability, 
direct costs, and opportunity costs were derived from 
primary data, unpublished and published sources.  
 The mean total cost (US$, year 2004 values) per 
vaccination, not including time cost, was estimated as 
$11.57 for pharmacies, $17.04 for mass vaccination 
clinics, and $28.67 at doctor’s office.  
 The mean waiting time for mass vaccination and 
pharmacy clinics was 12 minutes for both; the doctors 
waiting time was over 1 hour.  
 The reported mean cost per vaccine dose ranged from 
$7.48 in the pharmacy setting to $9.24 in the doctor’s 
office. 
 The patients’ time, labor, and overhead cost were 
higher in scheduled doctor visits. 
 
Discussion 
Pharmacists administering vaccines has effectively lowered 
health care cost and increased vaccination rates. The data 
compiled in this review has revealed ways pharmacists have 
been using their practice to advance the promotion and 
administration of the CDC recommended vaccinations. 
Pharmacists offer education, advertising, and incentives to 
reach patient populations in need of vaccinations. Pharmacies 
also have various conveniences such as extended hours, 
shortened wait times, ease of access for medically underserved 
patients in urban and rural areas, and reduced vaccination 
costs. 9-12,15 With 93% of Americans living within 5 miles of a 
community pharmacy, community pharmacists are one of the 
most readily accessible health care professionals in the United 
States.5 
 
The clinical data collected has shown that pharmacy 
convenience and public trust as a vaccinator group is not a 
unique characteristic of pharmacists in the United States.10, 11 
Many patients in the UK preferred to pay the pharmacist for an 
influenza vaccination instead of receiving it for free from their 
general practitioner.10,11  Several studies demonstrate that 
many patients in the UK and United States go to the pharmacy 
during lunch hours.7,10,11 Convenience is arguably the most 
advantageous characteristic of pharmacies as a vaccination 
location. In addition, many pharmacies are open 24 hours 
including holidays, allowing patients to receive vaccinations 
during these off-clinic hours.7    
 
Despite the convenience, various barriers such as state laws, 
collaboration protocols, and health plan restrictions further 
prevent pharmacies from administering the full CDC 
recommend schedule.  An estimated 40,000 to 50,000 adults 
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die annually from vaccine-preventable disease in the United 
States.5 Additionally, $10 billion dollars are used to treat 
patients without routine or recommended vaccinations.5 The 
state laws restricting pharmacists as a vaccinator are 
inconsistent and seemingly arbitrary (Table 3). Many state laws 
prevent pharmacists from providing vaccinations to the most 
cost-effective population—children. Some states limit the 
pharmacist to certain types of vaccines. The 2016 ACPE 
accreditation standards for the doctor of pharmacy curriculum 
requires pharmacy schools to provide training for students to 
become certified in administering injections.21 Furthermore, 
biologics and vaccines are considered pharmaceutical products 
approved through the FDA, which positions pharmacists as 
vaccine experts.  The expertise provided by pharmacists was 
demonstrated in Haas-gehres a, et al. where pharmacy 
interventions significantly decreased missed opportunities for 
scheduled vaccinations.16 Vaccination protocols, prescription 
only orders and standing orders are additional barriers to 
patient access to pharmacy service.  Also, both commercial and 
state health plans do not readily cover all scheduled vaccines5 
when administered in the pharmacy setting, further hindering 
healthcare. With the inconsistent restrictions and lack of 
medical standard, research concerning protocols and orders 
would assist in determining the practicality of these 
restrictions.   
 
Economically, vaccines delivered in the pharmacy lower the 
cost for health care.17,18 Patients have higher direct and 
opportunity costs when getting vaccinations at their physician’s 
office.18,19 A recent study has shown the average opportunity 
cost per physician visit was $43, which exceeds the average 
patient’s out-of-pocket payment. Total opportunity costs per 
year for all physician visits in the United States were $52 billion 
in 2010.19 Studies have shown that receiving vaccines in the 
pharmacy setting was the least expensive option for patients. 
In contrast, vaccines delivered in the traditional physical office 
setting are the most expensive.17,18 The patient may also 
experience opportunity costs due to office wait times or 
appointment co-pays.17-19 Compounding the inconveniences of 
going to a physician office has made many patients appreciate 
the prompt service in the pharmacy setting. Additional 
electronic technologies within pharmacy software systems 
have enabled pharmacists to identify risk groups in need of 
vaccinations. Researchers have conducted a study using claims 
data as an identifying tool.14 Moreover, patients visit their 
pharmacies more frequently, thus facilitating the verification of 
vaccine history and minimizing missed opportunities.  
 
After reviewing the literature, pharmacy practice should 
enhance the pharmacist’s role as a vaccinator by including 
complete vaccination records with the patient’s medication 
profile.  The community pharmacy serves as a valuable source 
of history for each patient’s prescriptions records, and adding 
the vaccination history to the patient profile will help identify 
those who have not received their recommended vaccinations 
according to the CDC guidelines. The vaccination history 
developed by the pharmacist will also serve as a tool to assist 
various medical personnel involved with the patient.  Also, 
insurance companies should extend pharmacy insurance 
benefits to cover vaccines as a preventative pharmaceutical 
measure against disease. Expanding vaccines coverage in the 
pharmacy setting will bring current those who are irregularly 
vaccinated and increase vaccination rates in hard-to-reach 
populations.12  
 
The following are research proposals that can measure the 
clinical and economic impact of the pharmacist as a vaccinator: 
comparisons of direct cost and opportunity cost for the full 
vaccination schedule administered at the community pharmacy 
vs. the physician’s office, cost effectiveness of travel vaccines 
given in a community pharmacy setting, a study to determine 
or estimate the average number of vaccinations a pharmacy 
administers annually, an observational claims analysis of 
rejected vaccinations by an insurance provider in the 
community setting, and a literature review of pharmacy 
protocols and state law limitations. 
 
Conclusion 
Pharmacists as vaccinators are an underutilized vaccine 
provider source.  This literature review reveals a pattern among 
studies measuring pharmacists’ impact on vaccine rates, 
patient preferences, and cost savings. Expanding the 
pharmacists’ ability to vaccinate more population groups 
through the changing legislation has traditionally increased 
vaccination rates by state.13 Inconsistency exists within the 
health benefits system, which complicates pharmacy 
vaccination efforts.  Vaccination is the most cost effective way 
to prevent infectious disease and comorbid complications, 
however commercial and governmental health plans provide 
limited coverage for receiving vaccinations from a pharmacy.5 
Pharmacists have demonstrated to be dependable, accurate, 
and cost effective vaccination providers. State laws, collaborate 
agreement protocols, and health plans have prevented patients 
from using the pharmacy to receive all CDC recommended 
vaccines which can potentially delay the Healthy People 2020 
goal of increasing vaccination rates and reducing preventable 
infectious diseases.  
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Table 1: Clinical 
Name of Study and 
Description 
Type of Study / Objectives Methods Results Implications 
Vaccinations 
administered during 
off-clinic hours. 
Increasing patient 
access and 
convenience.7  
 
Goad Ja et al. Ann 
Fam Med. 
2013;11(5):429-36 
 
Retrospective review. 
 
Objective: Analyze the 
types of vaccine 
administered and patient 
pharmacies population 
vaccinated during off clinic 
hours in a nationally 
community pharmacy. 
One-year vaccination review 
chain pharmacy. 
 
Categorized by traditional 
hours (9am-6m) vs. off clinic 
hours (evening, holidays, 
weekends). 
 
Compared demographic and 
types of vaccines. 
Pharmacist administered 
6,250,402 vaccinations. 
 
30.5% provided during off 
clinic hours. 
 
Patients had higher odds of 
off-clinic vaccination if they 
were younger than 65, male, 
reside in urban area, and did 
not have chronic conditions.  
 
17.5% of all vaccines 
administered during lunch 
hours (11 am -1 pm). 
 
Patients are more likely to use 
off clinic hours if they were 
vaccinated in states that 
authorize pharmacist to all 
CDC-recommended vaccines 
vs. states that authorize 
pharmacist to administer 
influenza, pneumonia and 
zoster (OR = 1.0044; 95% CI, 
1.040-1.049). 
 
The typical off clinic hour user, 
male, young, heather patient, 
reside highlighter more likely to 
be vaccinated during off-clinical 
hours. 
 
Community pharmacies are 
expanding the access and 
convenience of vaccines.  
 
Working population utilize the 
convenience outside the 
working hours thus increases 
vaccination rates.  
 
Patient seek vaccinations at 
times most convenient to them.  
 
Expanding the pharmacist ability 
to administer adults and 
children for all vaccines in all 
states will have the greatest 
impact on vaccination rates.  
Community 
pharmacist-
administered 
influenza 
immunization 
improves patient 
access to vaccines8 
 
 
Papastergiou J et al. 
Can Pharm J (Ott). 
2014; 147(6):359-65 
 
Objective: 
 To describe the 
demographics of patients 
receiving influenza vaccines 
in the community setting 
and to understand patient 
perceptions of pharmacy 
vaccinations. 
Survey collected at 4 
community pharmacy 
locations in Toronto in 8-
week period. 
1502 surveys were collected. 
 
86% of patient were very 
comfortable or comfortable 
14% with being vaccinated by 
pharmacist. 
 
92% of patients were very 
satisfied or satisfied 8% with 
pharmacies’ service and 
injection technique. 
 
28% of patients indicated that 
they would not have been 
vaccinated that year if the 
pharmacy service were not 
provided. 
 
46% of the patients had risk 
factors such as heart disease, 
respiratory disease, cancer, 
diabetes or was receiving 
immunosuppressant.  
Pharmacist have the potential to 
provide a positive effect on 
public health by improving 
vaccination rates among high 
risk patients and first time 
vaccine recipients.  
 
 
 
Expanding pharmacist 
vaccination services to cover 
other vaccines would improve 
patient access and would 
receive positive reception. 
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The effect of 
pharmacist 
intervention of 
Herpes Zoster 
Vaccination in 
community practice9 
 
Wang et al. J Am 
Pharm Assoc (2003). 
2013;53(1):46-53. 
 
Prospective interventional 
with pre-post design. 
 
Investigate whether 
intervention by community 
pharmacist promoting 
herpes zoster would result 
in an increased rate.  
 
Outcomes: 
Primary: Compare 
vaccination rates for herpes 
zoster during the period 
control and intervention 
period and patients. 
 
Secondary: evaluate 
relative efficacy of the 
pharmacy intervention two 
areas: educating patients 
about vaccine and influence 
patients to receive vaccine.  
 
Study of three pharmacies 
that serve suburban, semi-
rural, rural demographics.  
 
Two protocols: collaborative 
practice and Rx all vaccines 
Control period, patients who 
voluntary presented to 
pharmacy requesting herpes 
zoster vaccination. 4 weeks. 
 
Intervention period, release 
of newspaper press 
containing information on 
herpes zoster, every script 
dispense contained herpes 
zoster flyer, all patients 
profiles with CDC ACIP- 
recommend indications were 
identified and a one-time 
personal letter was sent 
containing the same 
information from the press 
release and flyer. 4 weeks. 
 
Vaccination rates increased 
from 0.37% (or 59/16,121) 
during the control period to 
1.20% (or 193/16,062) during 
the intervention period 
(P<0.0001). 
 
The number of survey 
respondents was 158 while 
193 individuals in pharmacy 
databases received the vaccine 
during the intervention period, 
giving a response rate over 
80%. 
 
There was no statistical 
difference when pharmacy-
based sources and 
family/friends were compared 
(P=0.1025). 
 
Patients were more likely to be 
influenced to receive the 
herpes zoster vaccination as a 
result of one of the pharmacist 
- driven interventions rather 
than a physician (P=0.0260) or 
other source (P<0.0001). 
 
The pharmacy-driven 
interventions, the personalized 
letter was more effective than 
all of the other interventions in 
influencing patients to receive 
the herpes zoster vaccine. 
 
205 patients who filled out a 
survey during the study, 204 
(99.5%) reported being either 
very comfortable or somewhat 
comfortable with the 
pharmacist administering the 
vaccine. 
 
Pharmacy sources were 
generally statistically more 
effective than were all other 
sources in educating people 
about the vaccine and 
influencing patients to receive 
the herpes zoster vaccination. 
The only exception was that 
there was no difference in 
efficacy of pharmacy sources 
and family members or friends 
in influencing patients to 
receive the vaccine. 
Pharmacists can attain better 
vaccine outcomes by 
communication with patients 
using mediums as personal 
letters. 
 
Pharmacists are a well-trusted 
source for vaccination 
information. 
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It’s easier in 
pharmacy”: why 
some patients prefer 
to pay for flu jabs 
rather than use the 
National Health 
Service.10 
 
Anderson C et al. 
BMC Health Serv Res. 
2014;14:35. 
 
 
This paper discusses 
retrospective data collected 
through a sample of Boots 
UK community pharmacies 
during 2012–13 to help 
support the case for 
national commissioning of 
flu vaccinations through 
pharmacy.  
 
Data were collected during 
the 2012–13 flu season as 
part of a community 
pharmacy private flu 
vaccination service to help 
identify whether patients 
were eligible to have their 
vaccination free of charge on 
the NHS. Additional data 
were collected from a sample 
of patients accessing the 
private service within 13 
pharmacies to help identify 
the reasons patients paid 
when they were eligible for 
free vaccination.  
 
Data were captured from 
89,011 privately paying 
patients across 479 pharmacies 
in England, of whom 6% were 
eligible to get the vaccination 
free. 921 patients completed a 
survey in the 13 pharmacies 
selected. Of these, 199 (22%) 
were eligible to get their flu 
vaccination for free. 131 (66%) 
were female. Average age was 
54 years. Of the 199 patients 
who were eligible for free 
treatment, 100 (50%) had been 
contacted by their GP surgery 
to go for their vaccination, but 
had chosen not to go. Reasons 
given include accessibility, 
convenience and preference 
for pharmacy environment. 
Patients would rather pay for 
convenience than wait for long 
time for free service. 
 
Who uses pharmacy 
for flu vaccinations? 
Population profiling 
through a UK 
pharmacy chain11 
 
Anderson C et al. Int J 
Clin Pharm. 
2016;38(2):218-22 
 
 To understand the profile 
of people accessing flu 
vaccination services within 
a large pharmacy chain.  
 
Retrospective data 
collected through a sample 
of in England during the 
2014/15 Flu season.  
 
 
Pharmacists requested 
people who had been 
vaccinated in 2014/15 to 
complete a questionnaire. 
Data was captured 
electronically on vaccine 
delivery levels across 1201 
pharmacies. Deprivation 
profiles were calculated using 
the Carstairs index.  
Carstairs index (used to 
calculate deprivation 
quintiles for least and most 
deprived); based on four 
census indicators: low social 
class, lack of car ownership, 
overcrowding, and male 
unemployment.  
1741 patients from a total of 
55 pharmacies completed the 
survey. Convenience and 
accessibility remain the key 
reasons for attending 
pharmacy.  
 
Pharmacy services are 
accessed by people from all 
postcode areas, including some 
from the most deprived 
localities.  
These services are highly 
accessed by patients from all 
socio demographic areas. 
Patients would rather pay for 
convenience than wait for long 
time for free service. 
 
Health professionals and 
working class people tend to use 
the pharmacy vaccine service. 
Individual- and 
Neighborhood-Level 
Characteristics 
Associated with 
Support of In-
Pharmacy 
Vaccination among 
ESAP-Registered 
Pharmacies: 
Pharmacists’ Role in 
Reducing 
Racial/Ethnic 
Disparities in 
Influenza 
Vaccinations  
in New York City12  
 
Crawford ND et al. J 
Urban Health. 
2011;88(1):176-85. 
 
New York State (NYS) 
passed legislation 
authorizing pharmacists to 
administer vaccines in 
2008. Racial/socioeconomic 
disparities persist in 
vaccination rates and 
vaccine-preventable 
diseases such as influenza. 
Many NYS pharmacies 
participate in the Expanded 
Syringe Access Program 
(ESAP), which allows 
provision of non-
prescription syringes to 
help prevent transmission 
of HIV, and are uniquely 
positioned to offer 
vaccination services to low-
income communities. To 
understand individual and 
neighborhood 
characteristics of pharmacy 
Used pharmacy staff baseline 
data to assess support of in- 
pharmacy vaccination, which 
was measured using a Likert 
scale (very supportive, 
somewhat supportive, not 
supportive, don’t know, and 
refused) in response to, “How 
much do you support 
vaccination services being 
provided in your pharmacy?” 
Persons who reported being 
very supportive or somewhat 
supportive were classified as 
supportive, and those who 
reported not supportive were 
classified as not supportive. 
Persons who reported don’t 
know and refused were 
excluded from this analysis 
(n=4). It is important to note 
that support of in-pharmacy 
vaccination reflects individual 
The sample consists of 437 
pharmacists, non- pharmacist 
owners, and technicians 
enrolled from 103 eligible New 
York City pharmacies. Using 
multilevel analysis, pharmacy 
staff that expressed support of 
in- pharmacy vaccination 
services were 69% more likely 
to support in-pharmacy HIV 
testing services (OR, 1.69; 95% 
CI 1.39–2.04).  
There was a total of 437 
pharmacy staff: 189 
pharmacists, 19 non-
pharmacist owners/managers, 
and 229 pharmacy 
technicians/clerks. Of these 
pharmacy staff, 38.7% were 
male, most were Hispanic 
(36.1%), followed by 
Asian/Pacific Islander (19.3%), 
African American (18.2%), 
Evidence-supporting scale-up of 
vaccination efforts in 
pharmacies located in foreign-
born/immigrant communities, 
which has potential to reduce 
disparities in vaccination rates 
and preventable influenza-
related mortality.  
The majority of pharmacy 
personnel are very supportive of 
in pharmacy vaccination despite 
sociodemographics disparities.   
Pharmacies that also offer other 
public health service are more 
likely to support in-pharmacy 
vaccinations.  
 
Pharmacies are in the key 
position to vaccinate too-hard-
to-reach population groups. 
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staff support for in-
pharmacy vaccination, we 
combined census tract data 
with baseline pharmacy 
data from the Pharmacies 
as Resources Making Links 
to Community Services 
(PHARM-Link) study among 
ESAP-registered 
pharmacies.  
 
attitudes and beliefs of this 
service rather than actual 
participation in current 
vaccination services in their 
pharmacy. Participants were 
probed about their level of 
support even if this service 
was not feasible in the 
pharmacy. Therefore, we 
refer to the reported beliefs 
and attitudes of in-pharmacy 
vaccination as in-pharmacy 
vaccination support. 
White (13.1%), South 
Asian/Indian/Pakistani (8.3%), 
and other race/ethnicity 
(5.1%). Pharmacy staff worked 
an average of 9.4 years in 
pharmacies. Most (86.3%) 
pharmacy staff supported 
vaccination being provided 
inside the pharmacy.  
 
 
The role of 
pharmacists in the 
delivery of influenza 
vaccinations13  
 
Steyer TE et al. 
Vaccine. 
2004;22(8):1001-6. 
 
The purpose of this study is 
to determine whether 
influenza vaccine rates 
have increased in states 
where pharmacists can give 
vaccines.  
 
To assess the impact of 
legislation allowing 
pharmacists to administer 
vaccine. 
 
For this analysis, the 1995 
and 1999 Behavioral Risk 
Factor Surveillance System 
(BRFSS) was used. The BRFSS 
is an annual telephone survey 
conducted by the Centers for 
Disease Control and 
Prevention that assesses 
health risks in the US. In this 
survey, individuals are asked, 
“During the past 12 months, 
have you had a flu shot?”  
 Sixteen states were taken 
from the BRFSS to compare 
influenza vaccination rates 
for individuals both 18–64 
and 65 years and older. Eight 
of these states (Arkansas, 
Kansas, Nebraska, North 
Dakota, Oklahoma, 
Tennessee, Texas and 
Virginia) passed legislation in 
1997 allowing pharmacists to 
administer vaccines while 
eight (Louisiana, Missouri, 
Iowa, Wyoming, Utah, West 
Virginia, Florida, and 
Maryland) had no legislation 
prior to 2000. Data for the 
years 1995 and 1999 were 
then analyzed.  
 
Secondary analysis of the 
Behavioral Risk Factor 
Surveillance System (BRFSS) 
from the years 1995 and 
1999. Information regarding 
legislation allowing 
pharmacists to administer 
vaccines was obtained from 
the American Pharmaceutical 
Association. 
 
 
Individuals aged 65 years and 
older who lived in states where 
pharmacists could provide 
vaccines had significantly 
higher (P < 0.01) influenza 
vaccine rates than individuals 
of this age who resided in 
states where pharmacists 
could not provide vaccines.  
 
Allowing pharmacists to provide 
vaccinations is associated with 
higher influenza vaccination 
rates for individuals aged 65 
years and older. 
 
Expanding the pharmacies 
ability to administer more 
vaccines increases vaccination 
rates in new populations. 
Expanding patient access and 
refining legal parameters in 
pharmacy practice has a 
correlated effect in the groups 
who are vaccinated.   
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Pharmacists as 
providers: Targeting 
pneumococcal 
vaccinations to high 
risk populations14 
Taitel M et al. 
Vaccine. 
2011;29(45):8073-6. 
 
The objective of this study 
was to evaluate the impact 
of pharmacists educating 
at-risk patients on the 
importance of receiving a 
pneumococcal vaccination. 
 
 
 
Using de-identified claims 
from a large, national 
pharmacy chain, all patients 
who had received an 
influenza vaccination 
between August 1, 2010 and 
November 14, 2010 and who 
were eligible for PPSV23 were 
identified for the analysis. 
Based on the Advisory 
Committee on Immunization 
Practices recommendations, 
at-risk patients were 
identified as over 65 years of 
age or as aged 2–64 with a 
comorbid conditions. A 
benchmark medical and 
pharmacy claims database of 
commercial and Medicare 
health plan members was 
used to derive a PPSV23 
vaccination rate typical of 
traditional care delivery to 
compare to pharmacy-based 
vaccination. Period incidence 
of PPSV23 was calculated and 
compared.  
 
Among the 1.3 million at-risk 
patients, 65,598 (4.88%) 
received a pneumococcal 
vaccine. This vaccination rate 
was significantly (p < .001) 
higher than the PPSV23 
benchmark rate of 2.90% 
(34,917/1,204,104). In the 
study group, PPSV23 rates 
varied by age group but not by 
gender. Patients aged 60–70 
years had the highest 
vaccination rate (6.60%, 
26,430/400,454) of any age 
group.  
 
Pharmacies have the ability to 
target at risk vaccination groups. 
Pharmacy electronic records can 
filter patient profiles based on 
risk factors characteristic. 
Pharmacies can expand this 
function to make more health or 
vaccine interventions and 
produce better outcomes for 
patients.  
 
These results support the 
expanding role of community 
pharmacists in the provision of 
wellness and prevention 
services. 
 
Pharmacies can help achieve the 
U.S. Department of Health and 
Human Services’ Healthy People 
goals for vaccine coverage. This 
study supports the expanding 
role of community pharmacists 
in the provision of wellness and 
prevention services.  
 
.  
 
Improved Influenza 
Vaccination Rates in 
a Rural Population as 
a Result of a 
Pharmacist-Managed 
Immunization 
Campaign15 
 
Van amburgh JA et 
al. Pharmacotherapy. 
2001;21(9):1115-22. 
 
To increase the rate of 
influenza vaccinations in 
high-risk patients by means 
of a pharmacist-managed 
immunization campaign.  
 Unblinded, single 
intervention. 
Rural primary care clinic. 
 
The pharmacy team 
developed an education 
packet that was sent to all 
patients who needed the 
influenza vaccine. The packet 
contained a letter and a two-
sided information insert 
designed in collaboration 
with a teaching/learning 
specialist.  
 
The pharmacy team 
developed two surveys. One 
survey, for patients who 
received the influenza 
vaccine (entitled “We helped 
you, now you can help us”), 
was given by a nurse or 
pharmacist to patients during 
the vaccination clinic, at 
physician appointments, or 
by mail.  
A follow-up letter and survey 
were mailed in early 
December to unvaccinated 
patients who had indications 
for vaccine. The primary 
focus was to encourage them 
to get vaccinated if they had 
not yet done so. 
 
Before intervention (1998), 
vaccination rates were low: 
182 (28%) patients with and 
102 (6%) patients without 
indications for the vaccine. 
After the pharmacy-directed 
intervention in 1999, 354 
(54%) patients with and 148 
(9%) patients without 
indications were successfully 
vaccinated. 
 
The influenza vaccination rate 
increased from 28% at baseline 
(before program initiation) to 
54% after program initiation. 
Unvaccinated patients were 
younger and resided in more 
urban areas than vaccinated 
patients; vaccinated patients 
had a higher frequency of 
cardiovascular disease or 
diabetes mellitus. Vaccinated 
patients consistently identified 
the education packet and their 
health care providers as 
primary motivators for 
vaccination.  
 
Total of 283 patients 
completed the “We helped 
you, now you can help us” 
survey. Of these, 199 
This study demonstrated that 
this pharmacy- directed 
program, which included a 
mailing and improved access to 
the influenza vaccine, 
significantly increased 
vaccinations by 95% for a group 
of high-risk patients in a rural 
community practice.  
The education packet received 
by mail was the most common 
reason patients were both 
convinced and reminded to get 
vaccinated.  
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respondents were patients 
with positive indications who 
were vaccinated against 
influenza and had received the 
education packet (56.4% 
response rate). Patients 
consistently identified the 
mailing and their health care 
provider as the top factors that 
had convinced and reminded 
them to get vaccinated.  
 
The most common suggestions 
for improving the vaccination 
program were to provide more 
days and times available to be 
vaccinated and to increase the 
number of providers to 
administer vaccinations. 
Impact of pharmacist 
integration in a 
pediatric primary 
care clinic on 
vaccination errors: A 
retrospective 
review16  
 
Haas-gehres A. J Am 
Pharm Assoc (2003). 
2014;54(4):415-8. 
 
To measure the impact of 
ambulatory clinical 
pharmacist integration in a 
pediatric.  
 
Primary care clinic on 
vaccination error rates and 
to evaluate missed 
opportunities.  
 
A retrospective, quasi-
experimental review of 
electronic medical records of 
visit encounters during a 3-
month period compared 
vaccine error rates and 
missed opportunities 
between two pediatric 
residency primary care clinics. 
The intervention clinic has a 
full-time ambulatory clinical 
pharmacist integrated into 
the health care team. 
 
Pharmacy services were not 
provided at the comparison 
clinic. A vaccine error was 
defined as follows: doses 
administered before 
minimum recommended age, 
doses administered before 
minimum recommended 
spacing from a previous dose, 
doses administered 
unnecessarily, live virus 
vaccination administered too 
close to a previous live 
vaccine, and doses invalid for 
combinations of these 
reasons. 
900 encounters were randomly 
selected and reviewed. The 
error rate was found to be 
0.28% in the intervention clinic 
and 2.7% in the comparison 
clinic. The difference in error 
rates was found to be 
significant (P = 0.0021). The 
number of encounters with 
greater than or equal to one 
missed opportunity was 
significantly higher in the 
comparison clinic compared 
with the intervention clinic 
(29.3% vs. 10.2%; P <0.0001).  
 
Pharmacist have the ability to 
identify CDC scheduled 
recommendation in pediatric 
population. 
 
Pharmacist can support 
ambulatory clinics to increase 
vaccination rates and decreases 
the rates of missed 
opportunities.  
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Table 2: Economics 
Name of study and 
description 
Type of study / objectives Methods Results Implications 
Cost of Adult 
vaccination in 
Medical Settings and 
Pharmacies: An 
observational study17 
 
Singhal PK et al. J 
Manag Care Spec 
Pharm. 
2014;20(9):930-6. 
 
Observational 
retrospective study.  
 
Objective: To examine 
whether the direct 
medical costs paid for 
adult vaccination differ by 
vaccination setting.  
 
This was an observational 
retrospective study using 
2010 MarketScan Commercial 
Claims and Encounters and 
Medicare Supplemental and 
Coordination of Benefits 
databases. Adults receiving 
herpes zoster or shingles 
vaccine, pneumococcal 
vaccine 23-valent, or 
influenza vaccines were 
identified using Current 
Procedural Terminology 
codes and National Drug Code 
numbers from medical and 
pharmacy claims files, 
respectively, between 
January 1 and December 31, 
2010, in 1 of the following 3 
settings: physician offices; 
other medical settings (e.g., 
inpatient/outpatient 
hospitals, emergency rooms); 
and pharmacies. Patients 
were adults aged 60 years on 
the date of zoster vaccination 
and aged 19 years on the 
date of pneumococcal or 
influenza vaccinations. The 
final study samples meeting 
inclusion/exclusion criteria 
were 54,042 for zoster 
vaccine, 154,994 for 
pneumococcal vaccine, and 
1,657,264 for influenza 
vaccine. The vaccination costs 
included the health plan and 
enrollee paid amounts for the 
product; vaccine 
administration; dispensing 
fee; and, where applicable, 
the visit. The mean (SD) 
vaccination costs paid per 
vaccine administrations were 
estimated by vaccine and 
type of setting, overall, and 
by geographic region and 
type of health plan. The costs 
paid for the same vaccine 
across vaccination settings 
were compared using analysis 
of variance with post hoc 
tests (Tukey).  
Of those receiving zoster, 
pneumococcal, and influenza 
vaccines, 25%, 1%, and 7%, 
respectively, received the 
vaccines at a pharmacy. 
Compared with other U.S. 
regions, pharmacy-based 
vaccination for these 3 
vaccines was generally more 
frequent in the West and the 
South.  
 
Mean (SD) costs paid per 
enrollee per vaccine 
administration at physician 
offices, other medical 
settings, and pharmacies 
were as follows: for zoster 
vaccine, $208.72 (42.10), 
$209.51 (50.83), and $168.50 
(15.66), respectively (P<0.05); 
for pneumococcal vaccine, 
$65.69 (27.54), $72.11 
(49.95), and $54.98 (9.72), 
respectively (P<0.05); and for 
influenza vaccine, $29.29 
(15.29), $24.20 (13.12), and 
$21.57 (6.63), respectively 
(P<0.05).  
 
For all 3 vaccines, the costs 
paid were significantly lower 
in pharmacies than in either 
physician offices or other 
medical settings (P < 0.05).  
 
The mean amounts paid also 
differed by geographic region 
and type of health plan, with 
costs usually lower for the 
vaccinations given at 
pharmacies.  
 
The average direct costs paid 
per adult vaccination were 
lower in pharmacies compared 
with physician offices and other 
medical settings by 16%-26% 
and 11%-20%, respectively. 
 
These results were mostly 
consistent across geographic 
regions and types of health 
plans.  
 
These data may help payers and 
policymakers understand the 
economic value of adult 
vaccination in different settings, 
especially in pharmacies. 
 
The data may also help medical 
or pharmacy insurance 
providers understand the 
economic value of expanding 
the vaccination schedule 
coverage to the pharmacy 
setting. 
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Non Traditional 
settings for influenza 
of Adults 
Costs and Cost 
Effectiveness18 
 
Prosser LA et al. 
Pharmacoeconomics. 
2008;26(2):163-78 
 
To describe the cost of 
vaccination in non-
traditional settings such 
as pharmacies and mass 
vaccinations clinics 
 
Evaluate the projected 
health benefits, cost and 
cost effectiveness of 
delivering influenza 
vaccinations to adults of 
varying ages and risk 
groups in non-traditional 
settings compared with 
schedule doctor’s office 
visits in the United States.   
 
 
Evaluated cost of influenza 
vaccinations in non-
traditional setting via detailed 
telephone interviews with 
vaccination clinics and 
pharmacists who administer 
vaccines  
 
Decision tree used to 
compare projected cost and 
health benefits of receiving 
an influenza vaccination from 
non-traditional setting or 
during schedule doctor office 
visit with no vaccination. 
 
Probabilities and cost (direct 
and opportunity) for 
uncomplicated influenza 
illness, outpatient visits, 
hospitalizations, deaths, 
vaccination and vaccine 
adverse events were derived 
from primary data and 
published and unpublished 
articles.  
 
The mean cost (2004 values) 
was lower in mass vaccination 
($17.04) and pharmacy 
($11.57) setting than in 
scheduled office visits. 
 
In non-traditional settings, 
cost savings was projected for 
healthy adults aged > 50 
years and for high-risk adults 
of all ages.  
 
For health adults 18-49 years 
was cost effective, prevention 
($US90) if vaccines delivered 
in pharmacy setting, $US210 
by mass vaccination, and 
$US870 by scheduled doctor’s 
office visit.   
 
 
Vaccinations given in the 
pharmacy setting is the most 
cost effective way to administer 
vaccines.  
 
Vaccines given in pharmacy can 
lower the cost to patients and to 
health providers.  
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Table 3: Modified: National Association of Boards of Pharmacy: Survey of Pharmacy Law20  
States  List of Conditions Pharmacist Administer Vaccination 
Alabama , Arizona, California, 
Colorado*, Delaware, District of 
Columbia, Georgia, Idaho, Illinois, 
Kentucky Louisiana, Maine*, 
Mississippi , Missouri, Nebraska 
Nevada*,New Hampshire, New Jersey, 
New Mexico, Puerto Rico, South 
Carolina, South Dakota,Tennessee, 
Texas, Vermont ,Virginia 
 
Allowed to vaccinate with fewer restricted measures.   
Alaska With board-approved collaborative practice protocol application. 
Arkansas, Kansas, Oregon, West 
Virginia 
 
Subject to vaccination protocol and completed course of study and training. 
Connecticut, With restrictions. (FL – Consultant pharmacist in nursing home setting. Section 465.0125, F.S.) 
Connecticut, Montana Pursuant to protocol only. (MT – Institutional protocol.) 
Connecticut If pursuant to a collaborative practice protocol. 
Florida, Pennsylvania, West Virginia Pharmacists may vaccinate if they are certified by the board to administer injectables. (PA – if registered.) 
Hawaii Pursuant to a licensed medical — doctor’s or osteopathic physician’s order and collaborative agreement and 
authorization. 
Indiana 
 
May administer vaccines under a drug order, prescription, or physician-approved protocol for influenza, 
shingles, pneumonia, tetanus, diphtheria, acellular pertussis, HPV, and meningitis. 
Iowa, Colorado, Maine, Nevada, Ohio 
 
Must be in accordance with a protocol. 
IA-By written protocol pursuant to rules of the Board of Pharmacy or when specifically directed by the 
prescriber for an individual patient.  
CO - Drug therapy management protocol.  
MI- May administer cholesterol, blood glucose, and international ratio, hepatitis C.  
NV – Protocol must be approved by the Board. 
OH – Pharmacists and pharmacy interns may dispense naloxone pursuant to a physician-approved protocol. 
They are not specifically authorized to “prescribe,” nor are they recognized as prescribers under Ohio law.) 
Maryland 
 
Statute allows pharmacists to administer influenza vaccines to individuals age nine and above; CDC-
recommended vaccinations to individuals ages 11 to 18 with prescription; CDC-recommended vaccines and 
travel vaccines to adults under a protocol. Pharmacists may also administer self- administered drugs. 
Regulations pending. Registration with the Board is required. 
Massachusetts Approved by Department of Public Health 
Michigan Yes, if it has been delegated to them and they have the approved training. See Section 16215 of the 
Michigan Public Health Code on delegation. 
Minnesota Influenza to patients six years of age and older, all other vaccines to patients 13 years of age or older. 
Written protocol with a physician, APRN, or PA. 
Montana 
 
Pharmacists are authorized to prescribe and administer vaccines without a collaborative practice agreement 
in place for the following vaccines: influenza to those 12 years and older; pneumococcal polysaccharide, 
tetanus, and diphtheria to those 18 years and older; herpes zoster to those identified in Centers for Disease 
Control and Prevention guidelines; and in the event an adverse reaction, epinephrine or diphenhydramine to 
those 12 years and older. 
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New York 
 
May administer influenza, pneumococcal, herpes zoster, meningococcal, and tetanus, diphtheria, and 
pertussis vaccines and drugs to treat reactions. 
North Carolina 
 
Influenza, pneumococcal, herpes, zoster, hepatitis B, meningococcal, tetanus-diphtheria, tetanus and 
diphtheria toxoids and peruses, tetanus and diphtheria toxoids and acellular pertussis, tetanus toxoid, and 
all other vaccinations recommended or required by the Centers for Disease Control and Prevention. 
North Dakota When trained and authorized by Board. 
Ohio Certain vaccines as listed in Ohio Revised Code §4729.41 and Board Rules. 
Oklahoma, On prescriber’s order.  
Rhode Island, West Virginia Limited to certain adult vaccines. (RI – And flu vaccines for children ages nine and older.) 
Utah 
 
For inpatient pharmacist via institutional protocol only pursuant to the Division of Occupational and 
Professional Licensing approved vaccine protocol. 
Washington The definition of the “practice of pharmacy” includes “drug administration.” (WA – Definition also includes 
the monitoring of drug therapy and use and the initiation or modification of drug therapy in accordance 
with written guidelines or protocols in a previously established collaborative drug therapy agreement 
between a pharmacist and practitioner authorized to prescribe drugs.) 
Washington 
 
If appropriately certified bases upon the 12-hour Centers for Disease Control and Prevention training 
program, the pharmacist can initiate vaccinations pursuant to a collaborative drug therapy agreement.   
Wisconsin Yes, if requirements for coursework and insurance are met. 
Wyoming Age 7 and older for certain vaccines.  
